

Interstitial Cystitis - Pipeline Insight, 2021

<https://marketpublishers.com/r/I2F3295E1C8EN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: I2F3295E1C8EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Interstitial Cystitis - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Interstitial Cystitis Understanding

Interstitial Cystitis: Overview

Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of IC may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. IC can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men.¹ However, more men may struggle with IC than researchers originally thought. Some research suggests that women are more likely to develop IC if they have a history of being sexually abused or physically traumatized

'Interstitial Cystitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Cystitis pipeline landscape is provided which includes the disease overview and Interstitial Cystitis treatment guidelines. The assessment part of the report embraces, in depth Interstitial Cystitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Cystitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Cystitis R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Cystitis.

Interstitial Cystitis Emerging Drugs Chapters

This segment of the Interstitial Cystitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interstitial Cystitis Emerging Drugs

Certolizumab pegol: UCB

Certolizumab pegol (Cimzia) developed by UCB, Belgium is a recombinant, humanized F(ab)' fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It is in phase 3 stage of development for the treatment of Interstitial cystitis.

SI-722: Seikagaku Corporation

SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku's proprietary glycosaminoglycan modification technology and drug delivery systems (DDS). SI-722 injected into the bladder is thought to demonstrate long-lasting improvement in the conditions of frequent urination and bladder pain by releasing a steroid with an anti-inflammatory effect. SI-722 has completed a Phase I clinical study in the U.S. In November 2019, it is starting a Phase I/II clinical study. This clinical study will evaluate the drug for safety, tolerability, and pharmacokinetics, and will conduct an exploratory evaluation of its effectiveness.

Further product details are provided in the report.....

Interstitial Cystitis: Therapeutic Assessment

This segment of the report provides insights about the different Interstitial Cystitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Interstitial Cystitis

There are approx. 10+ key companies which are developing the therapies for Interstitial Cystitis. The companies which have their Interstitial Cystitis drug candidates in the most advanced stage, i.e. phase III include, UCB.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Interstitial Cystitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interstitial Cystitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Cystitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Cystitis drugs.

Interstitial Cystitis Report Insights

- Interstitial Cystitis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Interstitial Cystitis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Interstitial Cystitis drugs?

How many Interstitial Cystitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Cystitis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interstitial Cystitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Interstitial Cystitis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Merck & Co

PureTech Health

Teva Pharmaceutical Industries

Integrative Therapeutics, Inc.

Lipella Pharmaceuticals, Inc.

Astellas Pharma

Seikagaku Corporation

UCB

Alivio Therapeutics

Urigen Pharmaceuticals

PureTech Health

Key Products

Gefapixant

LYT 503

Fremanezumab

Peppermint oil

LP-08

ASP6294

SI-722

Certolizumab

ALV 107

URG-101

LYT 503

Mirabegron

Contents

- Introduction
- Executive Summary
- Interstitial Cystitis: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- Certolizumab pegol: UCB
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Gefapixant: Merck & Co
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- Drug name: Company name
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

LYT 503: PureTech Health

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Interstitial Cystitis Key Companies

Interstitial Cystitis Key Products

Interstitial Cystitis- Unmet Needs

Interstitial Cystitis- Market Drivers and Barriers

Interstitial Cystitis- Future Perspectives and Conclusion

Interstitial Cystitis Analyst Views

Interstitial Cystitis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Interstitial Cystitis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Interstitial Cystitis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Interstitial Cystitis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/l2F3295E1C8EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l2F3295E1C8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970